Physician profile
Lynn Carollo
NPI 1518300177
$13,523.08
in general payments reported to CMS, 2019-2025
27 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,313 · 2022: $2,676 · 2023: $2,946 · 2024: $3,019 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,387 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,386.74 |
| Education | $147.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,463.38 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,887.11 | 2021-2024 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $1,103.35 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $1,002.61 | 2021-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $721.64 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $682.74 | 2021-2025 | |
| Ardelyx, INC. | $433.83 | 2022-2025 | Ibsrela |
| Celgene Corporation | $406.76 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $337.26 | 2021-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $285.85 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $274.82 | 2024-2025 | Vowst, Zenpep |
| Genzyme Corporation | $244.40 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $231.10 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $193.97 | 2021-2022 | |
| Qol Medical, LLC | $161.41 | 2021-2025 | Sucraid, Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $156.69 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $152.44 | 2021-2025 | |
| Exact Sciences Corporation | $136.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $114.08 | 2021-2024 | Clenpiq, Rebyota |
| Redhill Biopharma INC. | $108.68 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $86.15 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $78.12 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $75.79 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $70.06 | 2021-2023 | Suflave, Sutab |
| Lilly USA, LLC | $53.65 | 2024-2025 | Omvoh |
| Organon LLC | $49.85 | 2023 | Hadlima, Renflexis |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Carollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.